{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:09:37Z","timestamp":1789650577380,"version":"4.0.0"},"reference-count":56,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL167010"],"award-info":[{"award-number":["R01HL167010"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>Idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and systemic sclerosis-associated interstitial lung disease (SSc-ILD) share the same structural outcome: extracellular matrix (ECM) deposition. Whether this shared endpoint reflects shared or distinct molecular programs remains unresolved. Differential expression results from four GEO datasets representing IPF, HP, non-IPF ILD, and SSc-ILD were intersected with the 1027-gene human matrisome masterlist and classified by threshold-defined disease preference. All four diseases shared a 21-gene upregulated matrisome core, and the matrisome fraction rose with cross-disease sharing, from 4.3% of single-disease upregulated genes to 45.7% of genes upregulated in all four (significant Cochran\u2013Armitage trend), and the enrichment persisted when any single cohort was removed. Apparent disease preference was largely attributable to unequal statistical power: of 29 genes measurable in all four datasets, 24 showed a concordant sub-threshold effect in at least one comparator disease. Category composition of the threshold-defined signatures did not differ significantly between diseases, and the exploratory pathway panel is reported within diseases only, because significance scales with cohort size. In a within-cohort comparison of IPF with chronic HP in GSE150910, with platform, cohort, and control population held constant, matrisome genes were over-represented among the 2732 genes separating the two diseases, and 205 matrisome genes distinguished them. Fibrosing ILDs share a cross-cohort ECM core, and the apparent disease preference of the remaining signatures largely reflects differences in statistical power between cohorts. Disease-preferential matrisome expression is nonetheless detectable when disease and study are not confounded, so the limitation lies in threshold-based cross-study intersection rather than in the matrisome compartment itself.<\/jats:p>","DOI":"10.3390\/cimb48090951","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:41:35Z","timestamp":1789645295000},"page":"951","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shared and Disease-Preferential Matrisome Programs in Fibrosing Interstitial Lung Disease: Evidence from Cross-Cohort and Within-Cohort Analysis"],"prefix":"10.3390","volume":"48","author":[{"given":"Xu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pulin","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: Knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of Fibrotic Lung Diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","article-title":"Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: A case-cohort study","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-2600(13)70191-7","article-title":"Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: A prospective case-cohort study","volume":"1","author":"Morell","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS\/JRS\/ALAT Clinical Practice Guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1148\/radiol.2453061881","article-title":"Chronic hypersensitivity pneumonitis: Differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT","volume":"246","author":"Silva","year":"2008","journal-title":"Radiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","article-title":"Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT","volume":"71","author":"Walsh","year":"2016","journal-title":"Thorax"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.12-2685","article-title":"Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis","volume":"144","author":"Swigris","year":"2013","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"00016-2017","DOI":"10.1183\/23120541.00016-2017","article-title":"Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis","volume":"3","author":"Adegunsoye","year":"2017","journal-title":"ERJ Open Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1126\/science.1176009","article-title":"The extracellular matrix: Not just pretty fibrils","volume":"326","author":"Hynes","year":"2009","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nrm3896","article-title":"Mechanotransduction and extracellular matrix homeostasis","volume":"15","author":"Humphrey","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI71386","article-title":"Fibrotic extracellular matrix activates a profibrotic positive feedback loop","volume":"124","author":"Parker","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201204-0754OC","article-title":"Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation","volume":"186","author":"Booth","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201004082","article-title":"Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression","volume":"190","author":"Liu","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"M111.014647","DOI":"10.1074\/mcp.M111.014647","article-title":"The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices","volume":"11","author":"Naba","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.matbio.2015.06.003","article-title":"The extracellular matrix: Tools and insights for the \u201comics\u201d era","volume":"49","author":"Naba","year":"2016","journal-title":"Matrix Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"a004903","DOI":"10.1101\/cshperspect.a004903","article-title":"Overview of the matrisome\u2014an inventory of extracellular matrix constituents and functions","volume":"4","author":"Hynes","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01308","DOI":"10.7554\/eLife.01308","article-title":"Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters","volume":"3","author":"Naba","year":"2014","journal-title":"eLife"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Naba, A., Clauser, K.R., Whittaker, C.A., Carr, S.A., Tanabe, K.K., and Hynes, R.O. (2014). Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-518"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semcdb.2018.06.005","article-title":"The cancer matrisome: From comprehensive characterization to biomarker discovery","volume":"89","author":"Socovich","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rosas, I.O., Richards, T.J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A.E., Lindell, K.O., Cisneros, J., Macdonald, S.D., and Pardo, A. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050093"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1164\/ajrccm.158.5.9803115","article-title":"Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis","volume":"158","author":"Yokoyama","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1183\/09031936.02.00081102","article-title":"Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis","volume":"19","author":"Greene","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2401070","DOI":"10.1183\/13993003.01070-2024","article-title":"Transcriptomics of interstitial lung disease: A systematic review and meta-analysis","volume":"65","author":"He","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.15252\/msb.20156123","article-title":"Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair","volume":"11","author":"Schiller","year":"2015","journal-title":"Mol. Syst. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.18632\/aging.205530","article-title":"Transcriptomic and network analysis identifies shared and unique pathways and immune changes across fibrotic interstitial lung diseases","volume":"16","author":"Liu","year":"2024","journal-title":"Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26470","DOI":"10.1038\/s41598-024-77469-5","article-title":"Spatially resolved gene expression profiles of fibrosing interstitial lung diseases","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1164\/rccm.202001-0134OC","article-title":"Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures","volume":"202","author":"Furusawa","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.202103-0569OC","article-title":"Lung Microenvironments and Disease Progression in Fibrotic Hypersensitivity Pneumonitis","volume":"205","author":"McDonough","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"00191-2022","DOI":"10.1183\/23120541.00191-2022","article-title":"Matrix metalloproteinase-7 is increased in lung bases but not apices in idiopathic pulmonary fibrosis","volume":"8","author":"Jaffar","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Fan, D., and Kassiri, Z. (2020). Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00661"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hohne, K., Wagenknecht, A., Maier, C., Engelhard, P., Goldmann, T., Schliessmann, S.J., Plones, T., Trepel, M., Eibel, H., and Muller-Quernheim, J. (2024). Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6. Cells, 13.","DOI":"10.3390\/cells13030238"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1164\/rccm.201704-0784OC","article-title":"A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis","volume":"197","author":"Parker","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11452","DOI":"10.1073\/pnas.1106083108","article-title":"R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt\/beta-catenin signaling","volume":"108","author":"Carmon","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e33126","DOI":"10.7554\/eLife.33126","article-title":"R-spondins can potentiate WNT signaling without LGRs","volume":"7","author":"Lebensohn","year":"2018","journal-title":"eLife"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nsmb.2081","article-title":"Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1","volume":"18","author":"Malinauskas","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Poggi, L., Casarosa, S., and Carl, M. (2018). An Eye on the Wnt Inhibitory Factor Wif1. Front. Cell Dev. Biol., 6.","DOI":"10.3389\/fcell.2018.00167"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1902442","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Maher","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mullenbrock, S., Liu, F., Szak, S., Hronowski, X., Gao, B., Juhasz, P., Sun, C., Liu, M., McLaughlin, H., and Xiao, Q. (2018). Systems Analysis of Transcriptomic and Proteomic Profiles Identifies Novel Regulation of Fibrotic Programs by miRNAs in Pulmonary Fibrosis Fibroblasts. Genes, 9.","DOI":"10.3390\/genes9120588"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaba1972","DOI":"10.1126\/sciadv.aba1972","article-title":"Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis","volume":"6","author":"Habermann","year":"2020","journal-title":"Sci. Adv."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/9\/951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:29:39Z","timestamp":1789648179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/9\/951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cimb48090951"],"URL":"https:\/\/doi.org\/10.3390\/cimb48090951","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}